SATURDAY, OCTOBER 11, 2025 (Brochure: Download)

G = General Pharmacist CEU    T = Technician CEU

Emerging Role of Radiopharmaceuticals for Renal Cell Carcinoma

8:00am-9:30am P/T (1.5hrs CEUs)

Spencer Smith, PharmD, Clinical Nuclear Pharmacist Specialist, Michigan Medicine, University of MI

Upon completion of this activity, participants will be able to: Describe the pathophysiology, epidemiology, and treatment of renal cell carcinoma (RCC); Evaluate the results of recent

radiopharmaceutical clinical trials for RCC; Discuss potential applications of adiopharmaceuticals for RCC management.

UAN: 0675-0000-25-032-L01-P/T

Hosting a USP 825 Specific Inspection     

9:30am-11:00am P/T (1.5hrs CEUs)

Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings

Upon completion of this activity, participants will be able to: Review key components of UPS 825 and how to respond to corresponding audit questions during an inspection; Identify differences in USP 825 and how to highlight them to inspectors who may not be as familiar with nuclear regulations; Discuss the art of hosting an inspection.

UAN: 0675-0000-25-033-L07-P/T

Enhancing Safety in Nuclear Pharmacies: A Review of Radiation Safety

11:15am-12:45pm P/T (1.5hrs CEUs)

Willie Regits, PhD, Senior Director, Supply Chain and Corporate Radiation Safety Officer, Clarity Pharmaceuticals

Upon completion of this activity, participants will be able to: Identify key radiation hazards and safety risks; Review best practices in radiation safety; Promote continuous education for new technologies and procedures.

UAN: 0675-0000-25-034-L99-P/T

Long-Lived Impurities in Isotopes: Impact on Waste Handling and Disposal Approaches

12:45pm-2:15pm P/T (1.5hrs CEUs)

Yasmine Saboui, MS, Director of Process Engineering, CMC Group, Abdera Therapeutics, Consultant - Targeted Design Solutions

Upon completion of this activity, participants will be able to: List isotopes with long-lived radioactive impurities: focus on Ac 225, Pb 212 and At-211; Discuss challenges to detection and handling; Explain the impact on site licensing requirements.

UAN: 0675-0000-25-035-L01-P/T

SUNDAY, OCTOBER 12, 2025

ClinicalTrials.gov Dissected: Behind the Public Listings

8:00am-9:30am P/T (1.5hrs CEUs)

Becca Segrest, PharmD, Area Manager – Nuclear & Precision Health, Cardinal Health

Upon completion of this activity, participants will be able to: Evaluate how the radiopharmaceutical research pipeline has changed over time: Number of trials by disease state, Diagnostic vs Therapeutic, •By isotope; Identify common and emerging diagnostic & therapeutic isotopes being studied; Discuss what early trends indicate about the future theranostic pairs; Discuss practical considerations for nuclear medicine department readiness and radiotherapy facilities.

UAN: 0675-0000-25-036-L01-P/T

Statistics in Nuclear Medicine       

9:30am-11:00am P/T (1.5hrs CEUs)

Jonathan Baldwin, PhD, Senior BioStatistician, TigerMed BDM

Upon completion of this activity, participants will be able to: List the problems associated with low count statistics for nuclear medicine; Determine the statistical variation encountered in a typical nuclear counting experiment (precision and chi square); Explain what “sufficiently rigorous to allow statistical confidence in the results” means when applied to assigning BUD; Define Sensitivity, Specificity, Accuracy, False Predictive Fraction, and Positive Predictive Value.

UAN: 0675-0000-25-037-L99-P/T

Evolving Scope of Nuclear Pharmacists in Radiopharmaceutical Manufacturing Part 211

11:15am-12:45pm P/T (1.5hrs CEUs)

Jenna DeJoris, PharmD, RPh, ANP, Assistant Production Manager, Nuclear Pharmacist, SpectronRx

Upon completion of this activity, participants will be able to: Define the role of nuclear CMOs and CDMOs in radiopharmaceutical development and production; Describe the nuclear pharmacist’s contributions to compliance, quality assurance, regulatory interpretation, and documentation management; Identify career-relevant skills and responsibilities of pharmacists in manufacturing compared to traditional pharmacy practice; Examine regulatory challenges in radiopharmaceutical manufacturing, with emphasis on 21CFR Part 211 versus 21 CFR Part 212.

UAN: 0675-0000-25-038-L03-P/T

Neuroendocrine Tumors: A 2025 Update for Nuclear Pharmacists

12:45pm-2:15pm P/T (1.5hrs CEUs)

Garcia Simon Clark, PharmD, MS, ANP, CCP, BCNP, Kindred Healthcare, Pharmacy Supervisor

Upon completion of this activity, participants will be able to: Describe the 2022 WHO classification and principal clinical subtypes of NETs; Compare and contrast Ga-68 DOTATE PET/CT and 123 I-MIBG SPECT/CT in terms of mechanism, biodistribution, sensitivity, and clinical useacross NET subtypes; Evaluate radiopharmaceutical and systemic therapies – 177 Lu-Dotate PRRT, 131 I-MIBG therapy, somatostatin analogs, targeted TKIs and their evidence base; Design an optimized diagnostic therapeutic algorithm for a given NET patient, integrating imaging choice, biomarker data, and guideline directed treatments.

UAN: 0675-0000-25-039-L01-P*